Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [91]
- Comments [0]
- Validations
- Immunohistochemistry [2]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA1-39544 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ErbB2 (HER-2) Recombinant Rabbit Monoclonal Antibody (SP3)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- Heat-mediated antigen retrieval is recommended prior to staining, using a 10mM citrate buffer, pH 6.0, for 10 minutes followed by cooling at room temperature for 20 min. Following antigen retrieval, incubate samples with primary antibody for 30 min at room temperature. A suggested positive control is breast carcinoma.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Antibody clone number
- SP3
- Vial size
- 1 mL
- Concentration
- 0.122 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references Prognostic value of ErbB2/HER2 in human meningiomas.
Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule.
Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer.
Ki-67 Membranous Staining: Biologically Relevant or an Artifact of Multiplexed Immunofluorescent Staining.
Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers.
Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Role of epithelial-mesenchymal transition markers in triple-negative breast cancer.
Retrospective analysis of metastatic behaviour of breast cancer subtypes.
In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer.
A novel, automated technology for multiplex biomarker imaging and application to breast cancer.
Lobulitis in nonneoplastic breast tissue from breast cancer patients: association with phenotypes that are common in hereditary breast cancer.
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.
Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer.
Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancer.
Trastuzumab for the treatment of salivary duct carcinoma.
Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer.
False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ.
SP3, a reliable alternative to HercepTest in determining HER-2/neu status in breast cancer patients.
The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study.
Associations between the Expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and Clinicopathologic Parameters of Human Breast Ductal Carcinomas.
Effective application of the methanol-based PreservCyt(™) fixative and the Cellient(™) automated cell block processor to diagnostic cytopathology, immunocytochemistry, and molecular biology.
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.
Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor.
Association of aberrations in one-carbon metabolism with molecular phenotype and grade of breast cancer.
The 3-layered ductal epithelium in gynecomastia.
Increased FDG uptake in breast cancer is associated with prognostic factors.
Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach.
Cell cycle proteins predict recurrence in stage II and III colon cancer.
Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation.
Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers.
Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Molecular phenotypes of matched in situ and invasive components of breast carcinomas.
Tid1, CHIP and ErbB2 interactions and their prognostic implications for breast cancer patients.
Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy.
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
The β2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells.
HER2/neu revisited: quality and interpretive issues.
HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer.
The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer.
The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer.
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.
The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas.
Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma.
The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors.
Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer.
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.
Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Expression and mutational analysis of GATA3 in Malaysian breast carcinomas.
Clinicopathological significance of calreticulin in breast invasive ductal carcinoma.
The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey.
Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis.
RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ.
Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients.
Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance.
Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles.
Cytological criteria to predict basal phenotype of breast carcinomas.
An improved processing method for breast whole-mount serial sections for three-dimensional histopathology imaging.
Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer.
Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer.
Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma.
Toker cells revisited.
The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.
Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: an aCGH study.
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis.
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.
Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus.
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Down-regulation of claudin-2 in breast carcinomas is associated with advanced disease.
Parafibromin expression in breast cancer: a novel marker for prognostication?
Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases.
Clinical validation of a customized multiple signature microarray for breast cancer.
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry.
Prognostic factors in Hungarian breast cancer patients.
Preoperative and intraoperative diagnosis of low-grade adenosquamous carcinoma of the breast: potential diagnostic pitfalls.
Arnli MB, Winther TL, Lydersen S, Torp SH
PloS one 2018;13(10):e0205846
PloS one 2018;13(10):e0205846
Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule.
Dobosz M, Haupt U, Scheuer W
mAbs 2017 Jan;9(1):140-153
mAbs 2017 Jan;9(1):140-153
Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer.
Chung MJ, Lee JH, Kim SH, Suh YJ, Choi HJ
Medicine 2016 May;95(20):e3689
Medicine 2016 May;95(20):e3689
Ki-67 Membranous Staining: Biologically Relevant or an Artifact of Multiplexed Immunofluorescent Staining.
Wang D, Pang Z, Clarke GM, Nofech-Mozes S, Liu K, Cheung AM, Filkins RJ, Yaffe MJ
Applied immunohistochemistry & molecular morphology : AIMM 2016 Jul;24(6):447-52
Applied immunohistochemistry & molecular morphology : AIMM 2016 Jul;24(6):447-52
Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers.
Liu YX, Wang KR, Xing H, Zhai XJ, Wang LP, Wang W
Oncology letters 2016 Aug;12(2):1240-1256
Oncology letters 2016 Aug;12(2):1240-1256
Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
Matsumoto H, Thike AA, Li H, Yeong J, Koo SL, Dent RA, Tan PH, Iqbal J
Breast cancer research and treatment 2016 Apr;156(2):237-47
Breast cancer research and treatment 2016 Apr;156(2):237-47
The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N, Bozkurt KK, Başpınar Ş, Koçer M, Eroğlu HE, Akdeniz R, Akçil M
Pathology, research and practice 2015 Oct;211(10):740-7
Pathology, research and practice 2015 Oct;211(10):740-7
Role of epithelial-mesenchymal transition markers in triple-negative breast cancer.
Cheung SY, Boey YJ, Koh VC, Thike AA, Lim JC, Iqbal J, Tan PH
Breast cancer research and treatment 2015 Aug;152(3):489-98
Breast cancer research and treatment 2015 Aug;152(3):489-98
Retrospective analysis of metastatic behaviour of breast cancer subtypes.
Savci-Heijink CD, Halfwerk H, Hooijer GK, Horlings HM, Wesseling J, van de Vijver MJ
Breast cancer research and treatment 2015 Apr;150(3):547-57
Breast cancer research and treatment 2015 Apr;150(3):547-57
In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D, Atkinson J, Guevara CI, Zhang C, Kery V, Moon SJ, Virata C, Yang P, Lowe C, Pinkstaff J, Cho H, Knudsen N, Manibusan A, Tian F, Sun Y, Lu Y, Sellers A, Jia XC, Joseph I, Anand B, Morrison K, Pereira DS, Stover D
PloS one 2014;9(1):e83865
PloS one 2014;9(1):e83865
Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer.
Dean SJ, Perks CM, Holly JM, Bhoo-Pathy N, Looi LM, Mohammed NA, Mun KS, Teo SH, Koobotse MO, Yip CH, Rhodes A
American journal of clinical pathology 2014 Mar;141(3):323-33
American journal of clinical pathology 2014 Mar;141(3):323-33
A novel, automated technology for multiplex biomarker imaging and application to breast cancer.
Clarke GM, Zubovits JT, Shaikh KA, Wang D, Dinn SR, Corwin AD, Santamaria-Pang A, Li Q, Nofech-Mozes S, Liu K, Pang Z, Filkins RJ, Yaffe MJ
Histopathology 2014 Jan;64(2):242-55
Histopathology 2014 Jan;64(2):242-55
Lobulitis in nonneoplastic breast tissue from breast cancer patients: association with phenotypes that are common in hereditary breast cancer.
Gulbahce HE, Vanderwerf S, Blair C, Sweeney C
Human pathology 2014 Jan;45(1):78-84
Human pathology 2014 Jan;45(1):78-84
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.
Galletti G, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, Kirby BJ, Giannakakou P
Lab on a chip 2014 Jan 7;14(1):147-56
Lab on a chip 2014 Jan 7;14(1):147-56
Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer.
Kuijpers CC, Moelans CB, van Slooten HJ, Horstman A, Hinrichs JW, Al-Janabi S, van Diest PJ, Jiwa M
PloS one 2013;8(12):e82018
PloS one 2013;8(12):e82018
Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancer.
Vermeulen JF, Kornegoor R, van der Wall E, van der Groep P, van Diest PJ
PloS one 2013;8(1):e53353
PloS one 2013;8(1):e53353
Trastuzumab for the treatment of salivary duct carcinoma.
Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, Shreenivas AV, Tishler RB, Haddad RI
The oncologist 2013;18(3):294-300
The oncologist 2013;18(3):294-300
Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer.
Vlug EJ, van de Ven RA, Vermeulen JF, Bult P, van Diest PJ, Derksen PW
Cellular oncology (Dordrecht) 2013 Oct;36(5):375-84
Cellular oncology (Dordrecht) 2013 Oct;36(5):375-84
False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
Nunes CB, Rocha RM, Buzelin MA, Balabram D, de Souza Foureaux F, Porto SS, Gobbi H
Journal of clinical pathology 2013 Nov;66(11):946-50
Journal of clinical pathology 2013 Nov;66(11):946-50
Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
Gulbahce HE, Sweeney C, Surowiecka M, Knapp D, Varghese L, Blair CK
Human pathology 2013 Nov;44(11):2427-31
Human pathology 2013 Nov;44(11):2427-31
Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ.
Aguiar FN, Mendes HN, Cirqueira CS, Bacchi CE, Carvalho FM
Clinics (Sao Paulo, Brazil) 2013 May;68(5):638-43
Clinics (Sao Paulo, Brazil) 2013 May;68(5):638-43
SP3, a reliable alternative to HercepTest in determining HER-2/neu status in breast cancer patients.
D'Alfonso TM, Liu YF, Chen Z, Chen YB, Cimino-Mathews A, Shin SJ
Journal of clinical pathology 2013 May;66(5):409-14
Journal of clinical pathology 2013 May;66(5):409-14
The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study.
Prins MJ, Ruurda JP, van Diest PJ, van Hillegersberg R, Ten Kate FJ
Annals of oncology : official journal of the European Society for Medical Oncology 2013 May;24(5):1290-7
Annals of oncology : official journal of the European Society for Medical Oncology 2013 May;24(5):1290-7
Associations between the Expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and Clinicopathologic Parameters of Human Breast Ductal Carcinomas.
Do SI, Kim K, Kim DH, Chae SW, Park YL, Park CH, Sohn JH
Journal of breast cancer 2013 Jun;16(2):152-8
Journal of breast cancer 2013 Jun;16(2):152-8
Effective application of the methanol-based PreservCyt(™) fixative and the Cellient(™) automated cell block processor to diagnostic cytopathology, immunocytochemistry, and molecular biology.
van Hemel BM, Suurmeijer AJ
Diagnostic cytopathology 2013 Aug;41(8):734-41
Diagnostic cytopathology 2013 Aug;41(8):734-41
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.
Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT
Cancer research 2013 Aug 1;73(15):4885-97
Cancer research 2013 Aug 1;73(15):4885-97
Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor.
Macfarlane R, Seal M, Speers C, Woods R, Masoudi H, Aparicio S, Chia SK
The oncologist 2012;17(2):172-8
The oncologist 2012;17(2):172-8
Association of aberrations in one-carbon metabolism with molecular phenotype and grade of breast cancer.
Naushad SM, Pavani A, Rupasree Y, Divyya S, Deepti S, Digumarti RR, Gottumukkala SR, Prayaga A, Kutala VK
Molecular carcinogenesis 2012 Oct;51 Suppl 1:E32-41
Molecular carcinogenesis 2012 Oct;51 Suppl 1:E32-41
The 3-layered ductal epithelium in gynecomastia.
Kornegoor R, Verschuur-Maes AH, Buerger H, van Diest PJ
The American journal of surgical pathology 2012 May;36(5):762-8
The American journal of surgical pathology 2012 May;36(5):762-8
Increased FDG uptake in breast cancer is associated with prognostic factors.
Sanli Y, Kuyumcu S, Ozkan ZG, Işik G, Karanlik H, Guzelbey B, Turkmen C, Ozel S, Yavuz E, Mudun A
Annals of nuclear medicine 2012 May;26(4):345-50
Annals of nuclear medicine 2012 May;26(4):345-50
Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach.
Dekker TJ, Borg ST, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ
Breast cancer research : BCR 2012 Jun 13;14(3):R93
Breast cancer research : BCR 2012 Jun 13;14(3):R93
Cell cycle proteins predict recurrence in stage II and III colon cancer.
Belt EJ, Brosens RP, Delis-van Diemen PM, Bril H, Tijssen M, van Essen DF, Heymans MW, Beliën JA, Stockmann HB, Meijer S, Meijer GA
Annals of surgical oncology 2012 Jul;19 Suppl 3:S682-92
Annals of surgical oncology 2012 Jul;19 Suppl 3:S682-92
Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM
Breast cancer research and treatment 2012 Jan;131(2):413-24
Breast cancer research and treatment 2012 Jan;131(2):413-24
14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation.
Zheng G, Xiong Y, Yi S, Zhang W, Peng B, Zhang Q, He Z
FEBS letters 2012 Jan 20;586(2):163-8
FEBS letters 2012 Jan 20;586(2):163-8
Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers.
Rau KM, Huang CC, Chiu TJ, Chen YY, Lu CC, Liu CT, Pei SN, Wei YC
Experimental and therapeutic medicine 2012 Aug;4(2):231-236
Experimental and therapeutic medicine 2012 Aug;4(2):231-236
Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA, Brandwijk KI, Devilee P, Wesseling J, Hogervorst FB, Verhoef S, Nederlof PM
Breast cancer research and treatment 2012 Apr;132(2):379-89
Breast cancer research and treatment 2012 Apr;132(2):379-89
Molecular phenotypes of matched in situ and invasive components of breast carcinomas.
Martins D, Sousa B, Lopes N, Gomes M, Veronese L, Albergaria A, Paredes J, Schmitt F
Human pathology 2011 Oct;42(10):1438-46
Human pathology 2011 Oct;42(10):1438-46
Tid1, CHIP and ErbB2 interactions and their prognostic implications for breast cancer patients.
Jan CI, Yu CC, Hung MC, Harn HJ, Nieh S, Lee HS, Lou MA, Wu YC, Chen CY, Huang CY, Chen FN, Lo JF
The Journal of pathology 2011 Nov;225(3):424-37
The Journal of pathology 2011 Nov;225(3):424-37
Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy.
Lee DS, Kim SH, Suh YJ, Kim S, Kim HK, Shim BY
Japanese journal of clinical oncology 2011 Jul;41(7):854-66
Japanese journal of clinical oncology 2011 Jul;41(7):854-66
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
Barok M, Tanner M, Köninki K, Isola J
Cancer letters 2011 Jul 28;306(2):171-9
Cancer letters 2011 Jul 28;306(2):171-9
The β2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells.
Shi M, Liu D, Duan H, Qian L, Wang L, Niu L, Zhang H, Yong Z, Gong Z, Song L, Yu M, Hu M, Xia Q, Shen B, Guo N
Breast cancer research and treatment 2011 Jan;125(2):351-62
Breast cancer research and treatment 2011 Jan;125(2):351-62
HER2/neu revisited: quality and interpretive issues.
Ahmed SS, Iqbal J, Thike AA, Lim AS, Lim TH, Tien SL, Tan PH
Journal of clinical pathology 2011 Feb;64(2):120-4
Journal of clinical pathology 2011 Feb;64(2):120-4
HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
Boers JE, Meeuwissen H, Methorst N
Histopathology 2011 Feb;58(3):383-94
Histopathology 2011 Feb;58(3):383-94
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
Joosse SA, Brandwijk KI, Mulder L, Wesseling J, Hannemann J, Nederlof PM
Genes, chromosomes & cancer 2011 Feb;50(2):71-81
Genes, chromosomes & cancer 2011 Feb;50(2):71-81
Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer.
Heerma van Voss MR, van der Groep P, Bart J, van der Wall E, van Diest PJ
Cellular oncology (Dordrecht) 2011 Feb;34(1):3-10
Cellular oncology (Dordrecht) 2011 Feb;34(1):3-10
The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer.
Atahan K, Küpeli H, Gür S, Yiğitbaşı T, Baskın Y, Yiğit S, Deniz M, Cökmez A, Tarcan E
International journal of medical sciences 2011 Feb 12;8(2):148-55
International journal of medical sciences 2011 Feb 12;8(2):148-55
The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer.
Atahan K, Küpeli H, Gür S, Yiğitbaşı T, Baskın Y, Yiğit S, Deniz M, Cökmez A, Tarcan E
International journal of medical sciences 2011 Feb 12;8(2):148-55
International journal of medical sciences 2011 Feb 12;8(2):148-55
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Barok M, Tanner M, Köninki K, Isola J
Breast cancer research : BCR 2011 Apr 21;13(2):R46
Breast cancer research : BCR 2011 Apr 21;13(2):R46
Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.
Teng YH, Tan WJ, Thike AA, Cheok PY, Tse GM, Wong NS, Yip GW, Bay BH, Tan PH
Breast cancer research : BCR 2011 Apr 1;13(2):R35
Breast cancer research : BCR 2011 Apr 1;13(2):R35
The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas.
Rhodes A, Sarson J, Assam EE, Dean SJ, Cribb EC, Parker A
American journal of clinical pathology 2010 Oct;134(4):621-32
American journal of clinical pathology 2010 Oct;134(4):621-32
Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma.
Tan MH, Wong CF, Tan HL, Yang XJ, Ditlev J, Matsuda D, Khoo SK, Sugimura J, Fujioka T, Furge KA, Kort E, Giraud S, Ferlicot S, Vielh P, Amsellem-Ouazana D, Debré B, Flam T, Thiounn N, Zerbib M, Benoît G, Droupy S, Molinié V, Vieillefond A, Tan PH, Richard S, Teh BT
BMC cancer 2010 May 12;10:196
BMC cancer 2010 May 12;10:196
The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors.
Lee CM, Tannock IF
BMC cancer 2010 Jun 3;10:255
BMC cancer 2010 Jun 3;10:255
Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer.
Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010 Jan;23(1):123-33
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010 Jan;23(1):123-33
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.
Bueno-de-Mesquita JM, Nuyten DS, Wesseling J, van Tinteren H, Linn SC, van de Vijver MJ
Annals of oncology : official journal of the European Society for Medical Oncology 2010 Jan;21(1):40-7
Annals of oncology : official journal of the European Society for Medical Oncology 2010 Jan;21(1):40-7
Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, Nielsen TO
Breast cancer research and treatment 2010 Jan;119(1):53-61
Breast cancer research and treatment 2010 Jan;119(1):53-61
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Freedman OC, Amir E, Hanna W, Kahn H, O'Malley F, Dranitsaris G, Cole DE, Verma S, Folkerd E, Dowsett M, Clemons M
Breast cancer research and treatment 2010 Jan;119(1):155-61
Breast cancer research and treatment 2010 Jan;119(1):155-61
Expression and mutational analysis of GATA3 in Malaysian breast carcinomas.
Bong PN, Zakaria Z, Muhammad R, Abdullah N, Ibrahim N, Emran NA, Syed Hussain SN
The Malaysian journal of pathology 2010 Dec;32(2):117-22
The Malaysian journal of pathology 2010 Dec;32(2):117-22
Clinicopathological significance of calreticulin in breast invasive ductal carcinoma.
Lwin ZM, Guo C, Salim A, Yip GW, Chew FT, Nan J, Thike AA, Tan PH, Bay BH
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010 Dec;23(12):1559-66
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010 Dec;23(12):1559-66
The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey.
Tan YO, Han S, Lu YS, Yip CH, Sunpaweravong P, Jeong J, Caguioa PB, Aggarwal S, Yeoh EM, Moon H
Cancer 2010 Dec 1;116(23):5348-57
Cancer 2010 Dec 1;116(23):5348-57
Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
Holstege H, van Beers E, Velds A, Liu X, Joosse SA, Klarenbeek S, Schut E, Kerkhoven R, Klijn CN, Wessels LF, Nederlof PM, Jonkers J
BMC cancer 2010 Aug 24;10:455
BMC cancer 2010 Aug 24;10:455
Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis.
Boone J, van Hillegersberg R, Offerhaus GJ, van Diest PJ, Borel Rinkes IH, Ten Kate FJ
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2009;22(6):496-504
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2009;22(6):496-504
RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG, Uner A, Yildiz I, Guler G, Takahashi M
Pathology, research and practice 2009;205(6):403-8
Pathology, research and practice 2009;205(6):403-8
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ.
Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, Young E, Mukhopadhyay P, Yeh HW, Allred DC, Hu M, Polyak K, Rosen JM, Medina D
Breast cancer research : BCR 2009;11(5):R66
Breast cancer research : BCR 2009;11(5):R66
Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, Brockhoff G
Breast cancer research : BCR 2009;11(4):R50
Breast cancer research : BCR 2009;11(4):R50
Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients.
Munjal K, Ambaye A, Evans MF, Mitchell J, Nandedkar S, Cooper K
Asian Pacific journal of cancer prevention : APJCP 2009;10(5):773-8
Asian Pacific journal of cancer prevention : APJCP 2009;10(5):773-8
Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance.
Yu GZ, Chen Y, Wang JJ
Journal of cancer research and clinical oncology 2009 Oct;135(10):1331-9
Journal of cancer research and clinical oncology 2009 Oct;135(10):1331-9
Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles.
Lopes N, Sousa B, Vieira D, Milanezi F, Schmitt F
Histopathology 2009 Nov;55(5):594-9
Histopathology 2009 Nov;55(5):594-9
Cytological criteria to predict basal phenotype of breast carcinomas.
Dufloth RM, Alves JM, Martins D, Vieira DS, Chikota H, Zeferino LC, Schmitt F
Diagnostic cytopathology 2009 Nov;37(11):809-14
Diagnostic cytopathology 2009 Nov;37(11):809-14
An improved processing method for breast whole-mount serial sections for three-dimensional histopathology imaging.
Sun L, Wang D, Zubovits JT, Yaffe MJ, Clarke GM
American journal of clinical pathology 2009 Mar;131(3):383-92
American journal of clinical pathology 2009 Mar;131(3):383-92
Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer.
Rocha RM, Nunes CB, Sanches FS, Rocha GF, Oliveira FN, Reis-Filho JS, Lambros MB, Gobbi H
Revista da Associacao Medica Brasileira (1992) 2009 Mar-Apr;55(2):163-8
Revista da Associacao Medica Brasileira (1992) 2009 Mar-Apr;55(2):163-8
Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer.
Rocha RM, Nunes CB, Sanches FS, Rocha GF, Oliveira FN, Reis-Filho JS, Lambros MB, Gobbi H
Revista da Associacao Medica Brasileira (1992) 2009 Mar-Apr;55(2):163-8
Revista da Associacao Medica Brasileira (1992) 2009 Mar-Apr;55(2):163-8
Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma.
Rosa FE, Silveira SM, Silveira CG, Bérgamo NA, Neto FA, Domingues MA, Soares FA, Caldeira JR, Rogatto SR
BMC cancer 2009 Mar 23;9:90
BMC cancer 2009 Mar 23;9:90
Toker cells revisited.
Nofech-Mozes S, Hanna W
The breast journal 2009 Jul-Aug;15(4):394-8
The breast journal 2009 Jul-Aug;15(4):394-8
The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.
Wang L, Jiang Z, Sui M, Shen J, Xu C, Fan W
BMC cancer 2009 Jul 11;9:226
BMC cancer 2009 Jul 11;9:226
Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: an aCGH study.
Wang C, Iakovlev VV, Wong V, Leung S, Warren K, Iakovleva G, Arneson NC, Pintilie M, Miller N, Youngson B, McCready DR, Done SJ
Genes, chromosomes & cancer 2009 Dec;48(12):1091-101
Genes, chromosomes & cancer 2009 Dec;48(12):1091-101
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N, Ligtenberg MJ, Wessels LF, Axwijk P, Verhoef S, Hogervorst FB, Nederlof PM
Breast cancer research and treatment 2009 Aug;116(3):479-89
Breast cancer research and treatment 2009 Aug;116(3):479-89
Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis.
Hanley KZ, Siddiqui MT, Lawson D, Cohen C, Nassar A
Diagnostic cytopathology 2009 Apr;37(4):251-7
Diagnostic cytopathology 2009 Apr;37(4):251-7
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia-Echeverria C, Chène P
Breast cancer research : BCR 2008;10(2):R33
Breast cancer research : BCR 2008;10(2):R33
Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.
Crabb SJ, Bajdik CD, Leung S, Speers CH, Kennecke H, Huntsman DG, Gelmon KA
Breast cancer research : BCR 2008;10(1):R6
Breast cancer research : BCR 2008;10(1):R6
Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus.
van Dekken H, Hop WC, Tilanus HW, Haringsma J, van der Valk H, Wink JC, Vissers KJ
American journal of clinical pathology 2008 Nov;130(5):745-53
American journal of clinical pathology 2008 Nov;130(5):745-53
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Mar 1;14(5):1368-76
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Mar 1;14(5):1368-76
Down-regulation of claudin-2 in breast carcinomas is associated with advanced disease.
Kim TH, Huh JH, Lee S, Kang H, Kim GI, An HJ
Histopathology 2008 Jul;53(1):48-55
Histopathology 2008 Jul;53(1):48-55
Parafibromin expression in breast cancer: a novel marker for prognostication?
Selvarajan S, Sii LH, Lee A, Yip G, Bay BH, Tan MH, Teh BT, Tan PH
Journal of clinical pathology 2008 Jan;61(1):64-7
Journal of clinical pathology 2008 Jan;61(1):64-7
Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases.
Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG
Breast cancer research and treatment 2008 Jan;107(2):249-57
Breast cancer research and treatment 2008 Jan;107(2):249-57
Clinical validation of a customized multiple signature microarray for breast cancer.
Tan BK, Tan LK, Yu K, Tan PH, Lee M, Sii LH, Wong CY, Ho GH, Yeo AW, Chow PK, Koong HN, Yong WS, Lim DT, Ooi LL, Soo KC, Tan P
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jan 15;14(2):461-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jan 15;14(2):461-9
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Dec 10;26(35):5697-704
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Dec 10;26(35):5697-704
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
Ricardo SA, Milanezi F, Carvalho ST, Leitão DR, Schmitt FC
Journal of clinical pathology 2007 Sep;60(9):1001-5
Journal of clinical pathology 2007 Sep;60(9):1001-5
The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
Short SM, Yoder BJ, Tarr SM, Prescott NL, Laniauskas S, Coleman KA, Downs-Kelly E, Pettay JD, Choueiri TK, Crowe JP, Tubbs RR, Budd TG, Hicks DG
The breast journal 2007 Mar-Apr;13(2):130-9
The breast journal 2007 Mar-Apr;13(2):130-9
The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry.
Wong SC, Chan JK, Lo ES, Chan AK, Wong MC, Chan CM, Lam MY, Chan AT
Archives of pathology & laboratory medicine 2007 Jul;131(7):1047-55
Archives of pathology & laboratory medicine 2007 Jul;131(7):1047-55
Prognostic factors in Hungarian breast cancer patients.
Nádasi E, Anga B, Sándor J, Megyesi J, Kelemen D, Mottolese M, Natali PG, Hegedus G, Arany I, Ember I
Anticancer research 2007 Jan-Feb;27(1A):279-82
Anticancer research 2007 Jan-Feb;27(1A):279-82
Preoperative and intraoperative diagnosis of low-grade adenosquamous carcinoma of the breast: potential diagnostic pitfalls.
Ho BC, Tan HW, Lee VK, Tan PH
Histopathology 2006 Dec;49(6):603-11
Histopathology 2006 Dec;49(6):603-11
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of c-erbB-2/HER-2 using anti-c-erbB-2/HER-2 Monoclonal Antibody (Product # MA5-16348) in Breast Carcinoma Cancer Tissue. The recommened dilution for this antibody in immunohistochemistry applications is 1:100.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of ErbB2 using a monoclonal antibody (Product # MA1-39544).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 In vitro evaluation of Her2 expression and ADC cytotoxicity. The expression of Her2 and the in vitro cytotoxicity of the ADCs are evaluated in the HCC-1954, NCI-N87, MDA-MB-453 and MDA-MB-468 cell lines. (A) The cell surface expression of Her2 is measured via FACS for a panel of tumor cell lines. HCC-1954, MDA-MB-453 and NCI-N87 were selected as the Her2 expressing cell lines while MDA-MB-468 was selected as the Her2 negative cell line. MDA-MB-453 cells are resistant to Herceptin. (B) NCI-N87 and HCC-1954 tumor xenografts were evaluated for Her2 expression via IHC. (C) The in vitro cytotoxicity of the anti-Her2 ADCs were evaluated in the HCC-1954, NCI-N87, MDA-MB-453 and MDA-MB-468 cell lines.
